

8:00-11:30	CPSSA: Safety Workshop		
8:00-8:15	PART 1: Introduction		
15 min	Welcome and recap of safety, efficacy and access issues	Radoslaw Kaczmarek	United States
8:15-10:40	PART 2: Safety & efficacy		
8:15-9:00	Pipeline developments: Phase 1-3 clinical trial data		
15 min	Investigator therapies for hemophilia A and B	Pratima Chowdary	United Kingdom
15 min	Investigator therapies for VWD and rare bleeding disorders	Peter Lenting	France
15 min	Q&A		
9:00-10:00	New therapies: Real-world data and clinical practice patterns		
15 min	Emicizumab/Hemlibra: Low-dose	Rucha Patil	India
15 min	Fc-VWF-XTEN Fusion Protein/ALTUVIII0: 1st year real-world data	Amy Dunn	United States
15 min	Emicizumab optimization app: How to maximize the vial	Alfonso Iorio	Canada
15 min	Q&A		
10:00 - 10:20	Break		
10:20-10:40	Cryoprecipitate: Cautions and limitations		
10 min	Cryoprecipitate: Cautions and limitations	Glenn Pierce	United States
10 min	Q&A		
10:40-11:30	PART 3: Access		
10 min	Treatment options for low- and middle-income countries	Brian O'Mahony	Ireland
10 min	ACCESS gene therapy: Real-world evidence on access and economics	Brian O'Mahony	Ireland
10 min	Q&A		
10 min	Comparison of ISTH and WFH hemophilia treatment guidelines	Alok Srivastava	India
10 min	Q&A		